ISPOR Europe 2025 9-12 November
The Visible Analytics team will be in Glasgow this November and we look forward to meeting you there.Come meet us at our booth #920 and join us at one of our sessions.
See our full list of activities for ISPOR Europe 2025 below.
Monday 10 November
Integrating Capacity-Enhancing Innovations in Healthcare Systems: Are Current Methods Adequate to Demonstrate the Impact on Efficiency and Capacity? [17:00-18:00]
Moderator: Michela Canobbio, MS, Becton Dickinson, Milano, Italy
Panellists: Neil Hawkins, MSc, PhD, MBA, CStat, University of Glasgow, UK; Laura Sampietro-Colom, PhD, MD, Hospital Clinic de Barcelona, SABADELL, Spain; Lotte Steuten, MSc, PhD, Office of Health Economics, London, UK
Barriers and enablers to the adoption of innovative methods for health technology assessment (HTA) decision-making [17:00-18:00]
Moderator: Keith R Abrams, BSc, MSc, PhD, University of Warwick, UK
Panellists: Nicholas Latimer, MSc, PhD, SCHARR, University of Sheffield, UK; Rhiannon Owen, BSc, MSc, PhD, Swansea University, UK; Ursula Becker, MSc, Roche, Basel, Switzerland
Poster session 1
12:30 - 13:30 Discussion period
Bayesian Dynamic Borrowing to Enhance Evidence for New Therapies [CO26]
Sean Yiu, PhD1, Katya Galactionova2, Steven Yuen, MD3, Chris Skedgel, MA, PhD4, Isabelle DURAND ZALESKI, MD5, Maarten Jacobus Postma, PhD6, Mark Sculpher, PhD7, Keith R. Abrams, BSc, MSc, PhD8
1Roche Products Ltd, Welwyn Garden City, UK, 2Evidence Lead, Roche, Basel, Switzerland, 3Genentech, Inc, South San Francisco, USA, 4Office of Health Economics, London, UK, 5Hôpital de l’Hôtel Dieu, Université de Paris, CRESS, INSERM, INRA, URCEco, AP-HP, CRETEIL, France, 6University of Groningen, Groningen, Netherlands, 7University of York, York, UK, 8University of Warwick, UK
Poster session 2
18:00 - 19:00 Discussion period
Gatekeepers of science: evolving publishing policies in the age of AI [OP9]
Eric Manalastas, Juliette Thompson, Aditi Hombali, David A. Scott. Visible Analytics, Oxford, UK
Tuesday 11 November
Research Podium: Advancing Statistical Methods in Survival Analysis [076]
Predicting Treatment Effect on the Loss of Ability to Rise From Floor in Duchenne Muscular Dystrophy Using Individual Trajectories: An Application of Joint Modeling in FOR-DMD [10:15-11:15]
Tasnim Hamza, PhD1, Keith R. Abrams, BSc, MSc, PhD2, Rossella Belleli, MA, MPH1
1F. Hoffmann-La Roche, Basel, Switzerland, 2Visible Analytics, UK
HEOR Impact Cases in Oncology and Rare Disease [IC12]
Integrating Quantitative Patient and Carer Insights into HTA: The Impact of a Patient Organisation Survey on a NICE Appraisal [15:00-16:00]
Edit Remak, PhD, Partner and Director, Health Economics, Visible Analytics, Budapest, Hungary
Mind the Gaps: Managing Missing PRO Data in the Era of JCA for HTA Submissions [17:00-18:00]
Moderator: Miranda Cooper, BSc, MSc, AstraZeneca, Barcelona, Spain
Panellists: Neil Hawkins, MSc, PhD, MBA, CStat, University of Glasgow, UK; Olivier Chassany, PhD, MD, Assistance Publique–Hôpitaux de Paris (AP-HP), Paris, France; Gianluca Baio, PhD, University College London, UK
Poster session 4
18:00 – 19:00 Discussion period
Mind the Gap: A Need for Guidance on Modelling Disease Activity Outcomes in Economic Models [CO164]
Noemi Muszbek, MSc1, Joshua A Ray, BSc, MSc2
1Visible Analytics Ltd, Reading, UK, 2Viatris Innovation, Basel, Switzerland
Wednesday 12 November
Poster session 5
9:00 - 10:00 Discussion period
ROBERTA on the Job: A Proof-of-Concept Study of a Customised GPT Tool for Risk-of-Bias Assessment of Randomised Clinical Trials [MSR183]
Eric Manalastas, Juliette Thompson, Aditi Hombali, David A. Scott. Visible Analytics, Oxford, UK
The Mirage of Stability: Challenges of Predicting Disease Activity Over Time in Systemic Lupus Erythematosus (SLE) [CO245]
Peter Gal, MSc1, Darren Talbot, PhD2, David Isenberg, MD3, A E Clarke, MD4, Joshua A Ray, BSc, MSc5
1Visible Analytics, Budapest, Hungary, 2Viatris Innovation, Allschwil, Switzerland, 3University College London, UK, 4University of Calgary, Canada, 5Viatris Innovation, Basel, Switzerland
The Relationship Between Surrogate Endpoints and Overall Survival in Myelofibrosis Clinical Trials: Results from a Targeted Literature Review [CO247]
Louise Linsell, DPhil, MSc, BSc1, Yuxian Chen, MSc1, Federico Felizzi, BSc, MS, PhD2, Santiago Moreno, PhD2, Elisabetta Fenu, MSc2, Maria Papageorgiou, MSc, MBA3, Dave Ray, PharmD, MBA, MPH4, Neil Hawkins, MBA, MSc, PhD5, Keith R. Abrams, BSc, MSc, PhD6
1Visible Analytics Ltd, Oxford, UK, 2Menarini, Zurich, Switzerland, 3Menarini Stemline, Marousi, Greece, 4Karyopharm Therapeutics, Newton, MA, USA, 5University of Glasgow, UK, 6University of Warwick, UK
